These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36840349)

  • 1. Epigenetic therapies for neuroblastoma: immunogenicity awakens.
    Jiménez C; Moreno L; Segura MF
    Mol Oncol; 2023 May; 17(5):718-721. PubMed ID: 36840349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic modulation of neuroblastoma enhances T cell and NK cell immunogenicity by inducing a tumor-cell lineage switch.
    Cornel AM; Dunnebach E; Hofman DA; Das S; Sengupta S; van den Ham F; Wienke J; Strijker JGM; van den Beemt DAMH; Essing AHW; Koopmans B; Engels SAG; Lo Presti V; Szanto CS; George RE; Molenaar JJ; van Heesch S; Dierselhuis MP; Nierkens S
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36521927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined sialic acid and histone deacetylase (HDAC) inhibitor treatment up-regulates the neuroblastoma antigen GD2.
    van den Bijgaart RJE; Kroesen M; Wassink M; Brok IC; Kers-Rebel ED; Boon L; Heise T; van Scherpenzeel M; Lefeber DJ; Boltje TJ; den Brok MH; Hoogerbrugge PM; Büll C; Adema GJ
    J Biol Chem; 2019 Mar; 294(12):4437-4449. PubMed ID: 30670592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
    Bensaid D; Blondy T; Deshayes S; Dehame V; Bertrand P; Grégoire M; Errami M; Blanquart C
    Clin Epigenetics; 2018; 10():79. PubMed ID: 29946373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing poly (ADP-ribose) polymerase inhibition through combined epigenetic and immunotherapy.
    Prasanna T; Wu F; Khanna KK; Yip D; Malik L; Dahlstrom JE; Rao S
    Cancer Sci; 2018 Nov; 109(11):3383-3392. PubMed ID: 30230653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy.
    Park J; Thomas S; Munster PN
    Epigenomics; 2015; 7(4):641-52. PubMed ID: 26111034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the epigenetic processes to enhance antitumor immunity in small cell lung cancer.
    Luo H; Shan J; Zhang H; Song G; Li Q; Xu CX
    Semin Cancer Biol; 2022 Nov; 86(Pt 3):960-970. PubMed ID: 35189321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic Regulation of Cytosolic Phospholipase A2 in SH-SY5Y Human Neuroblastoma Cells.
    Tan CS; Ng YK; Ong WY
    Mol Neurobiol; 2016 Aug; 53(6):3854-3872. PubMed ID: 26162318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of epigenetic therapy on natural killer cell function and development in hematologic malignancy.
    Lordo MR; Stiff AR; Oakes CC; Mundy-Bosse BL
    J Leukoc Biol; 2023 May; 113(5):518-524. PubMed ID: 36860165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The HDAC Inhibitor Domatinostat Promotes Cell-Cycle Arrest, Induces Apoptosis, and Increases Immunogenicity of Merkel Cell Carcinoma Cells.
    Song L; Bretz AC; Gravemeyer J; Spassova I; Muminova S; Gambichler T; Sriram A; Ferrone S; Becker JC
    J Invest Dermatol; 2021 Apr; 141(4):903-912.e4. PubMed ID: 33002502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma.
    Spel L; Boelens JJ; van der Steen DM; Blokland NJ; van Noesel MM; Molenaar JJ; Heemskerk MH; Boes M; Nierkens S
    Oncotarget; 2015 Nov; 6(34):35770-81. PubMed ID: 26452036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of histone deacetylase inhibitors on immune cells and implications for cancer therapy.
    Moran B; Davern M; Reynolds JV; Donlon NE; Lysaght J
    Cancer Lett; 2023 Apr; 559():216121. PubMed ID: 36893893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Could interleukin-15 potentiate histone deacetylase inhibitor effects in haematological malignancy?
    Zdrenghea MT
    Med Hypotheses; 2013 Aug; 81(2):311-5. PubMed ID: 23669372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroblastoma: an ongoing cold front for cancer immunotherapy.
    Kennedy PT; Zannoupa D; Son MH; Dahal LN; Woolley JF
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37993280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human class II major histocompatibility complex gene transfer into murine neuroblastoma leads to loss of tumorigenicity, immunity against subsequent tumor challenge, and elimination of microscopic preestablished tumors.
    Hock RA; Reynolds BD; Tucker-McClung CL; Kwok WW
    J Immunother Emphasis Tumor Immunol; 1995 Jan; 17(1):12-8. PubMed ID: 7728302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reactivation of silenced α-N-catenin induces retinoic acid sensitivity in neuroblastoma cells.
    Clark RA; Newton M; Qiao J; Lee S; Chung DH
    Surgery; 2021 Nov; 170(5):1546-1553. PubMed ID: 34092372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone Deacetylase Inhibitors in Cancer Therapy.
    Sun Y; Sun Y; Yue S; Wang Y; Lu F
    Curr Top Med Chem; 2018; 18(28):2420-2428. PubMed ID: 30526462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic modulation in cancer immunotherapy.
    Gallagher SJ; Shklovskaya E; Hersey P
    Curr Opin Pharmacol; 2017 Aug; 35():48-56. PubMed ID: 28609681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint molecules in neuroblastoma: A clinical perspective.
    Pathania AS; Prathipati P; Murakonda SP; Murakonda AB; Srivastava A; Avadhesh ; Byrareddy SN; Coulter DW; Gupta SC; Challagundla KB
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):247-258. PubMed ID: 35787940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitors and epigenetic regulation in lymphoid malignancies.
    Markozashvili D; Ribrag V; Vassetzky YS
    Invest New Drugs; 2015 Dec; 33(6):1280-91. PubMed ID: 26423245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.